Fidaxomicin

Clostridioides difficile infection is the leading cause of hospital-acquired diarrhea worldwide. Previously commonly used drugs such as vancomycin and metronidazole have clinical pain points of high recurrence rate and significant disturbance of intestinal flora. The advent of fidaxomicin provides a better option for the treatment of such infections. As the first macrolide narrow-spectrum anti-anaerobic drug, it specifically kills Clostridioides difficile by inhibiting the σ subunit of bacterial RNA polymerase, with almost no effect on the normal intestinal flora, and can be used for both adult and pediatric patients with Clostridioides difficile-associated diarrhea. Its clinical positioning is a first-line drug for mild to moderate Clostridioides difficile infection, especially suitable for people at high risk of recurrence.

At present, the global fidaxomicin market size is close to 600 million US dollars, with a compound annual growth rate maintained at around 9%. The growth momentum mainly comes from the increased demand for nosocomial infection prevention and control and the expansion of pediatric indications. The domestic market is still in the early stage of development. In the past, due to the high price of the original research drug, the annual sales volume was less than 100 million yuan. With the successive approval of generic drugs and the implementation of medical insurance negotiations, the market size is expected to exceed 500 million yuan in the next three years. In terms of competitive landscape, only 2 domestic enterprises have obtained approval for generic preparations at present, and large-scale production capacity layout has not yet emerged on the API supply side, leaving a large market gap.

The original research enterprise of fidaxomicin is Astellas Pharma, and the original brand name is Dificid. Its core compound patent expires in the United States in 2027, and the core compound patent in China expired in 2023. The main dosage form approved for the original research drug is oral tablet with a specification of 200mg, which has been included in the FDA Reference Listed Drug Catalog, and also included in the *Catalog of Reference Preparations for Chemical Drugs* of China. Up to now, no Chinese enterprise has obtained the marketing approval of fidaxomicin API, and there is no valid registration number on the CDE API registration platform for the time being. The approved preparation products in China are all imported original research products and generic preparations from 2 domestic enterprises. (Data as of October 2024, please refer to the official CDE website for the latest information.)

CATO can provide a full set of fidaxomicin impurity reference standards, most of which are in stock. For in-stock products, orders placed before 16:00 will be shipped on the same day. All products meet the compliance requirements of multiple regulations such as Chinese Pharmacopoeia and FDA, and can fully meet the use needs of different scenarios such as API R&D, quality research and consistency evaluation.